Drugs & Targets FDA Approves BMS’s Opdivo for Head and Neck Cancer Indication November 11, 2016Vol.42 No.42
Drugs & Targets VENTANA ALK (D5F3) CDx gets FDA approval to use on the VENTANA BenchMark ULTRA automated slide stainer November 11, 2016Vol.42 No.42
Drugs & Targets LEE011, Novartis’s selective cyclin dependent kinase inhibitor, granted FDA Priority Review November 11, 2016Vol.42 No.42
Drugs & Targets Roche Receives FDA Approval for Tecentriq Complementary Diagnostic in NSCLC November 04, 2016Vol.42 No.41
Drugs & Targets Hoffmann-LaRoche’s Alecensaro receives Health Canada approval NSCLC November 04, 2016Vol.42 No.41
Drugs & Targets BMS receives Health Canada conditional approval for Opdivo-Yervoy combination November 04, 2016Vol.42 No.41
Drugs & Targets Xtandi Receives FDA Approval for Supplemental New Drug Application October 28, 2016Vol.42 No.40
Drugs & Targets Keytruda Is First Checkpoint Inhibitor To Get Approval for Front Line NSCLC October 28, 2016Vol.42 No.40
Drugs & Targets Lartruvo Gets Accelerated Approval for Sarcoma; Tecentriq Approved for a Type of NSCLC October 21, 2016Vol.42 No.39
